HIV Prevention: SA Lenacapavir 2-Shot Injection Solution
PRETORIA — The Department of Health has officially introduced Lenacapavir, a next-generation long-acting HIV prevention injection, into the South African public health system. Health Minister Dr Aaron Motsoaledi confirmed that the rollout builds upon a decade of strategic health system strengthening and the existing primary healthcare infrastructure.
Lenacapavir marks a significant shift in the country’s HIV strategy. Unlike the traditional daily oral pre-exposure prophylaxis (PrEP) pills, this new treatment is administered via two injections every six months. Clinical trials have demonstrated unprecedented effectiveness in preventing HIV infection, offering a solution to the adherence barriers often associated with daily medication.
The introduction of this long-acting injectable is not a replacement for current methods but an addition to the national HIV prevention choice framework. South Africa has already initiated more than 2.2 million people on oral PrEP since 2016, establishing one of the most mature prevention platforms globally. The new injection is expected to be particularly beneficial for vulnerable populations, including adolescent girls, young women, and sex workers.
Government officials emphasized that the country’s existing primary healthcare infrastructure, trained workforce, and supply chain systems have created the necessary environment for this rapid rollout. While initial implementation is supported by international partners, the government has reaffirmed its commitment to long-term domestic financing as more affordable generic versions of the drug become available.
The public interest in this medical advancement is substantial, as it addresses the logistical challenges of daily pill-taking which has historically hindered prevention efforts. By integrating these injections into routine primary healthcare services alongside TB screening and maternal health, the department aims to accelerate the goal of ending new HIV infections.
This move reinforces South Africa’s position at the forefront of global health innovation. The Department of Health continues to coordinate with regulatory authorities and civil society to ensure that the rollout is equitable and reaches those at the highest risk of infection across all nine provinces.
Anyone with additional information relating to this story can contact us through email press@townpress.co.za.